



ASX RELEASE

VOLPARA SIGNS COLLABORATION AGREEMENT WITH AMBRY GENETICS

Wellington, NZ, 15th April 2020: Volpara Health Technologies Limited (**Volpara**; ASX: VHT), a medical technology company whose cancer screening software platform assists in the delivery of personalized patient care, has partnered with Ambry Genetics®, one of the world's leading genetic testing companies to bring a new era of breast care to patients in the United States.

Highlights of the agreement:

- Volpara plans to create an online ordering process for genetic testing within the Aspen® Breast practice management software, including using Volpara®Density™ for an automated breast density measure and subsequent risk calculation.
- Volpara will market Ambry's CARE Program™ (Comprehensive, Assessment, Risk, and Education) within the United States.
- As part of this collaboration agreement with Ambry, Volpara has the potential to significantly increase ARPU upon successful clinical implementation.
- Patients who qualify for supplemental imaging based on genetic results or risk assessments may benefit from early cancer detection.

Ambry Genetics, part of Konica Minolta Precision Medicine, is a leading clinical genetic testing company that has developed the CARE program. The CARE Program is a precision medicine platform that aligns with existing guidelines to help ensure more patients get access to recommended care. Volpara will automate parts of the workflow to make it easier for women to get this potentially life-saving additional screening and testing.

At least one Volpara software product is used in over 27% of women who attend screening each year in the United States. Customers utilize VolparaDensity for automated breast density assessment, an important breast cancer risk factor, along with breast cancer risk assessment modules in Aspen Breast (acquired from MRS Systems, Inc. in June 2019). These software products help providers confidently make informed decisions about triaging patients to supplemental imaging and/or genetic testing based on risk.

Risk assessment is also required by insurance companies to justify reimbursement for additional testing. Both, supplemental screening and genetic testing, assist in earlier cancer detection which is critical in reducing treatment costs, and increasing the chances of survival.

"Personalization of breast cancer screening based on risk is being adopted at a fast pace in the US, and Volpara is proud to be playing a major role in that. Our partnership with Ambry will allow us to offer additional value to our customers to ensure the right patients get the right testing at the right time", said the CEO of Volpara, Dr. Ralph Highnam, "With extra value from our platform, we expect to see a further increase in ARPU that we can achieve at each site".

Tom Schoenherr, Chief Commercial Officer of Ambry Genetics, said: "We are excited about this partnership opportunity and the ability to help give providers confidence and peace-of-mind in elevating the standard of care for their patients".

ENDS.

Authorisation and Additional Information

This announcement was authorised by the CEO Dr Ralph Highnam.



For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Communications
kwilliamson@we-worldwide.com
t: +61 3 9866 4722

ABOUT VOLPARA HEALTH TECHNOLOGIES LIMITED (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$95 million, including A\$55 million in June 2019. VHT is based in Wellington, New Zealand.

At the end of June 2019, VHT acquired MRS, a company based in Seattle, WA. MRS provides mammography reporting systems to over 1,600 breast clinics and hospitals, and to VHT a much stronger US presence, experienced local headquarters, and accelerated sales through cross-selling opportunities.

For more information, visit www.volparasolutions.com.